{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:30:57Z","timestamp":1768969857360,"version":"3.49.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0116023","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T18:51:52Z","timestamp":1420051912000},"page":"e116023","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model"],"prefix":"10.1371","volume":"9","author":[{"given":"Sonya","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Hai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D. R.","family":"Setchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"ref1","unstructured":"Grabowski GA, Petsko GA, Kolodny EH (2010) Gaucher Disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, et al. editors. Metabolic and Molecular Bases of Inherited Disease (OMMBID Mark II). New York: McGraw-Hill Companies, Inc."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"KS Hruska","year":"2008","journal-title":"Hum Mutat"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"V Koprivica","year":"2000","journal-title":"Am J Hum Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"E Sidransky","year":"2004","journal-title":"Mol Genet Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/jhg.2014.5","article-title":"Novel mutations in the glucocerebrosidase gene of Indian patients with Gaucher disease","volume":"59","author":"C Ankleshwaria","year":"2014","journal-title":"J Hum Genet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/jhg.2013.60","article-title":"A common and two novel GBA mutations in Thai patients with Gaucher disease","volume":"58","author":"R Tammachote","year":"2013","journal-title":"J Hum Genet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1515\/jpem-2012-0155","article-title":"Analysis of the beta-glucocerebrosidase gene in Turkish Gaucher disease patients: mutation profile and description of a novel mutant allele","volume":"25","author":"E Karaca","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bcmd.2010.07.010","article-title":"Clinical and genetic characteristics of Korean patients with Gaucher disease","volume":"46","author":"SY Jeong","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcmd.2006.11.003","article-title":"Gaucher disease among Chinese patients: review on genotype\/phenotype correlation from 29 patients and identification of novel and rare alleles","volume":"38","author":"FY Choy","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"NG Conradi","year":"1984","journal-title":"Acta Neuropathol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher&apos;s disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"VL Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"IB Enquist","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels","volume":"94","author":"YH Xu","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"YH Xu","year":"2003","journal-title":"Am J Pathol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"H Mizukami","year":"2002","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","article-title":"Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction","volume":"111","author":"EI Ginns","year":"2014","journal-title":"Mol Genet Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"SP Sardi","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"K Sango","year":"1995","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases","volume":"5","author":"D Phaneuf","year":"1996","journal-title":"Hum Mol Genet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1016\/S0021-9258(18)91935-6","article-title":"Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain","volume":"243","author":"S Basu","year":"1968","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1083\/jcb.117.2.259","article-title":"Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions","volume":"117","author":"D Jeckel","year":"1992","journal-title":"J Cell Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1073\/pnas.93.10.4638","article-title":"Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis","volume":"93","author":"S Ichikawa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1006\/bbrc.1998.9855","article-title":"Molecular cloning and characterization of the mouse ceramide glucosyltransferase gene","volume":"253","author":"S Ichikawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1073\/pnas.96.16.9142","article-title":"A vital role for glycosphingolipid synthesis during development and differentiation","volume":"96","author":"T Yamashita","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.1073\/pnas.0500893102","article-title":"Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth","volume":"102","author":"R Jennemann","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Shen W, Henry AG, Paumier KL, Li L, Mou K, et al. (2014) Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem.","DOI":"10.1111\/jnc.12672"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e1001506","DOI":"10.1371\/journal.pbio.1001506","article-title":"Neuronal expression of glucosylceramide synthase in central nervous system regulates body weight and energy homeostasis","volume":"11","author":"V Nordstrom","year":"2013","journal-title":"PLoS Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0005-2736(86)90285-3","article-title":"Topology of glucosylceramide synthesis in Golgi membranes from porcine submaxillary glands","volume":"858","author":"H Coste","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bj2800295","article-title":"Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver","volume":"2)","author":"AH Futerman","year":"1991","journal-title":"Biochem J 280 (Pt"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/jbc.274.1.451","article-title":"Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase","volume":"274","author":"DL Marks","year":"1999","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature06097","article-title":"Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide","volume":"449","author":"G D'Angelo","year":"2007","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.200704091","article-title":"Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis","volume":"179","author":"D Halter","year":"2007","journal-title":"J Cell Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1194\/jlr.R003996","article-title":"Multi-system disorders of glycosphingolipid and ganglioside metabolism","volume":"51","author":"YH Xu","year":"2010","journal-title":"J Lipid Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbalip.2008.01.004","article-title":"Functions of sphingolipid metabolism in mammals\u2014lessons from genetic defects","volume":"1781","author":"F Sabourdy","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.semcdb.2004.03.006","article-title":"Glycosphingolipids in engineered mice: insights into function","volume":"15","author":"K Furukawa","year":"2004","journal-title":"Semin Cell Dev Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"J Marshall","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e21758","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"KM Ashe","year":"2011","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"J Marshall","year":"2010","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","article-title":"Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis","volume":"94","author":"E Elliot-Smith","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy","volume":"93","author":"B Hess","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1523\/JNEUROSCI.2287-07.2007","article-title":"Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy","volume":"27","author":"H Ramakrishnan","year":"2007","journal-title":"J Neurosci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/oxfordjournals.jbchem.a124584","article-title":"The synthetic pathway for glucosylsphingosine in cultured fibroblasts","volume":"116","author":"Y Yamaguchi","year":"1994","journal-title":"J Biochem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/mgme.1998.2709","article-title":"Translational inefficiency of acid beta-glucosidase mRNA in transgenic mammalian cells","volume":"64","author":"YH Xu","year":"1998","journal-title":"Mol Genet Metab"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"16746","DOI":"10.1016\/S0021-9258(19)89454-1","article-title":"Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase","volume":"269","author":"X Qi","year":"1994","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1096\/fj.02-1053fje","article-title":"The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs","volume":"17","author":"RJ Veldman","year":"2003","journal-title":"FASEB J"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e57560","DOI":"10.1371\/journal.pone.0057560","article-title":"Substrate compositional variation with tissue\/region and Gba1 mutations in mouse models\u2013implications for Gaucher disease","volume":"8","author":"Y Sun","year":"2013","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1194\/jlr.M500202-JLR200","article-title":"Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants","volume":"46","author":"Y Sun","year":"2005","journal-title":"J Lipid Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1526-968X(200011\/12)28:3\/4<106::AID-GENE30>3.0.CO;2-T","article-title":"Widespread recombinase expression using FLPeR (flipper) mice","volume":"28","author":"FW Farley","year":"2000","journal-title":"Genesis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Y Sun","year":"2012","journal-title":"J Biol Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","article-title":"Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model","volume":"5","author":"YH Xu","year":"2010","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(68)90990-2","article-title":"Gaucher cells in chronic granulocytic leukaemia","volume":"2","author":"WC Smith","year":"1968","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V33.2.379.379","article-title":"Gaucher cells in chronic myelocytic leukemia: an acquired abnormality","volume":"33","author":"HE Kattlove","year":"1969","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/jcp.41.9.960","article-title":"Sea-blue histiocytes and Gaucher cells in bone marrow of patients with chronic myeloid leukaemia","volume":"41","author":"PR Kelsey","year":"1988","journal-title":"J Clin Pathol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nchembio.392","article-title":"An update on sphingosine-1-phosphate and other sphingolipid mediators","volume":"6","author":"H Fyrst","year":"2010","journal-title":"Nat Chem Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbalip.2008.06.002","article-title":"Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate","volume":"1781","author":"C Mao","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.1074\/jbc.M005142200","article-title":"Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens","volume":"275","author":"AD Tepper","year":"2000","journal-title":"J Biol Chem"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/glycob\/8.9.885","article-title":"Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways","volume":"8","author":"BK Gillard","year":"1998","journal-title":"Glycobiology"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"34372","DOI":"10.1074\/jbc.M703329200","article-title":"Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2","volume":"282","author":"H Le Stunff","year":"2007","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"E Lloyd-Evans","year":"2008","journal-title":"Nat Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cellsig.2007.12.006","article-title":"The sphingolipid salvage pathway in ceramide metabolism and signaling","volume":"20","author":"K Kitatani","year":"2008","journal-title":"Cell Signal"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-2275(20)39441-4","article-title":"Ceramide-like synthetic amides that inhibit cerebroside galactosidase","volume":"13","author":"RC Arora","year":"1972","journal-title":"J Lipid Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-3084(80)90057-2","article-title":"Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain","volume":"26","author":"RR Vunnam","year":"1980","journal-title":"Chem Phys Lipids"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"LL Bennett","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","article-title":"Eliglustat: first global approval","volume":"74","author":"RM Poole","year":"2014","journal-title":"Drugs"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases","volume":"55","author":"JA Shayman","year":"2014","journal-title":"J Lipid Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1010335505357","article-title":"Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy","volume":"24","author":"FM Platt","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"DJ Kuter","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment","volume":"53","author":"E Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"N Belmatoug","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease","volume":"35","author":"JA Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"E Lukina","year":"2010","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"M Jeyakumar","year":"1999","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0116023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T19:43:36Z","timestamp":1650915816000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0116023"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Dardis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0116023","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]}}}